Featured Stories
Resverlogix: The Future of Drug Development
Donald McCaffrey, President & CEO of Resverlogix will be featured on CEO Clips on the BNN Bloomberg channel airing October 9 & 10 © 2021 www.B-TV.com ....
Learn More
Apabetalone meets primary endpoint in PAH pilot study
Resverlogix reported that its lead drug apabetalone met its primary endpoint in a pulmonary arterial hypertension or ‘PAH’ investigator led pilot study. Watch the news...
Learn More
EVERSANA & Resverlogix Discuss Partnership On PharmaVOICE Webinar
Rohit Sood, EVP, COMPLETE Commercialization, EVERSANA / Donald McCaffrey, President & CEO, Resverlogix: Next Generation Commercial Innovation: Moving From Promise to Practice.
Learn More
Donald McCaffrey featured on Innovators with Jane King
Donald McCaffrey, President & CEO of Resverlogix featured on Innovators with Jane King. Latest updates on the Company's COVID-19 program.
Learn More
COVID-19 Program Update with Donald McCaffrey
CEO Donald McCaffrey joined PBA à Noon, for a live webinar and Q&A, to discuss the latest developments in Resverlogix' COVID-19 program.
Learn More
Health Canada Authorizes COVID-19 Clinical Study
Resverlogix receives "No Objection Letter" from Health Canada, approving the COVID-19 Clinical Trial Application for apabetalone.
Learn More
Apabetalone May Prevent Heart Damage Caused by COVID-19
COVID-19 affects not only lung and respiratory tissue but can injure your heart as well. One study, published in the Journal of the American Medical Association, found that 78% of recently...
Learn More
Balancing Epigenetics in the Treatment of Chronic Kidney Disease
Kidneys are the body’s filtration system . They clean our blood, removing waste and helping manage blood pressure by controlling the outflow of water. Unfortunately, when these filters...
Learn More
Targeting Epigenetics as a New Therapy in Vascular Disease and Dementia
Cardiovascular disease literally means disease of the heart and blood vessels, but it can cause additional life-altering complications that we might not initially associate with the disease,...
Learn More
The Faces of Cardiovascular Disease: Series Final
This is the final article of the mini-series, The Faces of Cardiovascular Disease , looking at the different presentations, symptoms, and root causes of a disease that affects millions of men...
Learn More
The Faces of Cardiovascular Disease: Part 4
This article is part of a mini-series, The Faces of Cardiovascular Disease , looking at the different presentations, symptoms, and root causes of a disease that affects millions of men and women...
Learn More
The Faces of Cardiovascular Disease: Part 3
This article is part of a mini-series, The Faces of Cardiovascular Disease , looking at the different presentations, symptoms, and root causes of a disease that affects millions of men and women...
Learn More
The Faces of Cardiovascular Disease: Part 2
This article is part of a mini-series, The Faces of Cardiovascular Disease , looking at the different presentations, symptoms, and root causes of a disease that affects millions of men and women...
Learn More
The Faces of Cardiovascular Disease: Part 1
This article is part of a mini-series we are calling The Faces of Cardiovascular Disease , looking at the different presentations, symptoms, and root causes of a disease that affects millions of...
Learn More
Apabetalone: A Relative Size Animation
Our lead compound – apabetalone – is the first small molecule of its kind with potentially important benefits for patients with high-risk cardiovascular and other chronic diseases. But...
Learn More